New therapeutic agents for metastatic colorectal cancer: literature review
This article provides an overview of drugs for metastatic colorectal cancer that are currently being evaluated in clinical trials. We discuss possible drug combinations and outlooks of their use in different lines of therapy. In addition to VEGF and EGFR inhibitors, we describe the molecules with fu...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
M. V. Zabelin [verfasserIn] S. S. Gordeev [verfasserIn] S. O. Kochkina [verfasserIn] A. A. Kostin [verfasserIn] A. A. Fedenko [verfasserIn] L. O. Petrov [verfasserIn] E. V. Gameeva [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2018 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Тазовая хирургия и онкология - “ABV-press” Publishing house”, LLC, 2021, 8(2018), 4, Seite 34-46 |
|---|---|
| Übergeordnetes Werk: |
volume:8 ; year:2018 ; number:4 ; pages:34-46 |
| Links: |
|---|
| DOI / URN: |
10.17650/2220-3478-2018-8-4-34-46 |
|---|
| Katalog-ID: |
DOAJ030787157 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ030787157 | ||
| 003 | DE-627 | ||
| 005 | 20230501181613.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2018 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.17650/2220-3478-2018-8-4-34-46 |2 doi | |
| 035 | |a (DE-627)DOAJ030787157 | ||
| 035 | |a (DE-599)DOAJba1ad87a2f634b9f871c88d0ed32999d | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a M. V. Zabelin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New therapeutic agents for metastatic colorectal cancer: literature review |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a This article provides an overview of drugs for metastatic colorectal cancer that are currently being evaluated in clinical trials. We discuss possible drug combinations and outlooks of their use in different lines of therapy. In addition to VEGF and EGFR inhibitors, we describe the molecules with fundamentally new mechanisms of action that can significantly expand the list of anticancer agents and increase the number of possible lines of therapy. | ||
| 650 | 4 | |a colorectal cancer | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a targeted drugs | |
| 650 | 4 | |a egfr inhibitors | |
| 650 | 4 | |a vegf inhibitors | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a S. S. Gordeev |e verfasserin |4 aut | |
| 700 | 0 | |a S. O. Kochkina |e verfasserin |4 aut | |
| 700 | 0 | |a A. A. Kostin |e verfasserin |4 aut | |
| 700 | 0 | |a A. A. Fedenko |e verfasserin |4 aut | |
| 700 | 0 | |a L. O. Petrov |e verfasserin |4 aut | |
| 700 | 0 | |a E. V. Gameeva |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Тазовая хирургия и онкология |d “ABV-press” Publishing house”, LLC, 2021 |g 8(2018), 4, Seite 34-46 |w (DE-627)176063123X |x 26869594 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2018 |g number:4 |g pages:34-46 |
| 856 | 4 | 0 | |u https://doi.org/10.17650/2220-3478-2018-8-4-34-46 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/ba1ad87a2f634b9f871c88d0ed32999d |z kostenfrei |
| 856 | 4 | 0 | |u https://ok.abvpress.ru/jour/article/view/265 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2686-9594 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2018 |e 4 |h 34-46 | ||
| author_variant |
m v z mvz s s g ssg s o k sok a a k aak a a f aaf l o p lop e v g evg |
|---|---|
| matchkey_str |
article:26869594:2018----::eteaetcgnsomtsaiclrcacne |
| hierarchy_sort_str |
2018 |
| callnumber-subject-code |
RC |
| publishDate |
2018 |
| allfields |
10.17650/2220-3478-2018-8-4-34-46 doi (DE-627)DOAJ030787157 (DE-599)DOAJba1ad87a2f634b9f871c88d0ed32999d DE-627 ger DE-627 rakwb rus RC254-282 M. V. Zabelin verfasserin aut New therapeutic agents for metastatic colorectal cancer: literature review 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This article provides an overview of drugs for metastatic colorectal cancer that are currently being evaluated in clinical trials. We discuss possible drug combinations and outlooks of their use in different lines of therapy. In addition to VEGF and EGFR inhibitors, we describe the molecules with fundamentally new mechanisms of action that can significantly expand the list of anticancer agents and increase the number of possible lines of therapy. colorectal cancer chemotherapy targeted drugs egfr inhibitors vegf inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens S. S. Gordeev verfasserin aut S. O. Kochkina verfasserin aut A. A. Kostin verfasserin aut A. A. Fedenko verfasserin aut L. O. Petrov verfasserin aut E. V. Gameeva verfasserin aut In Тазовая хирургия и онкология “ABV-press” Publishing house”, LLC, 2021 8(2018), 4, Seite 34-46 (DE-627)176063123X 26869594 nnns volume:8 year:2018 number:4 pages:34-46 https://doi.org/10.17650/2220-3478-2018-8-4-34-46 kostenfrei https://doaj.org/article/ba1ad87a2f634b9f871c88d0ed32999d kostenfrei https://ok.abvpress.ru/jour/article/view/265 kostenfrei https://doaj.org/toc/2686-9594 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 8 2018 4 34-46 |
| spelling |
10.17650/2220-3478-2018-8-4-34-46 doi (DE-627)DOAJ030787157 (DE-599)DOAJba1ad87a2f634b9f871c88d0ed32999d DE-627 ger DE-627 rakwb rus RC254-282 M. V. Zabelin verfasserin aut New therapeutic agents for metastatic colorectal cancer: literature review 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This article provides an overview of drugs for metastatic colorectal cancer that are currently being evaluated in clinical trials. We discuss possible drug combinations and outlooks of their use in different lines of therapy. In addition to VEGF and EGFR inhibitors, we describe the molecules with fundamentally new mechanisms of action that can significantly expand the list of anticancer agents and increase the number of possible lines of therapy. colorectal cancer chemotherapy targeted drugs egfr inhibitors vegf inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens S. S. Gordeev verfasserin aut S. O. Kochkina verfasserin aut A. A. Kostin verfasserin aut A. A. Fedenko verfasserin aut L. O. Petrov verfasserin aut E. V. Gameeva verfasserin aut In Тазовая хирургия и онкология “ABV-press” Publishing house”, LLC, 2021 8(2018), 4, Seite 34-46 (DE-627)176063123X 26869594 nnns volume:8 year:2018 number:4 pages:34-46 https://doi.org/10.17650/2220-3478-2018-8-4-34-46 kostenfrei https://doaj.org/article/ba1ad87a2f634b9f871c88d0ed32999d kostenfrei https://ok.abvpress.ru/jour/article/view/265 kostenfrei https://doaj.org/toc/2686-9594 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 8 2018 4 34-46 |
| allfields_unstemmed |
10.17650/2220-3478-2018-8-4-34-46 doi (DE-627)DOAJ030787157 (DE-599)DOAJba1ad87a2f634b9f871c88d0ed32999d DE-627 ger DE-627 rakwb rus RC254-282 M. V. Zabelin verfasserin aut New therapeutic agents for metastatic colorectal cancer: literature review 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This article provides an overview of drugs for metastatic colorectal cancer that are currently being evaluated in clinical trials. We discuss possible drug combinations and outlooks of their use in different lines of therapy. In addition to VEGF and EGFR inhibitors, we describe the molecules with fundamentally new mechanisms of action that can significantly expand the list of anticancer agents and increase the number of possible lines of therapy. colorectal cancer chemotherapy targeted drugs egfr inhibitors vegf inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens S. S. Gordeev verfasserin aut S. O. Kochkina verfasserin aut A. A. Kostin verfasserin aut A. A. Fedenko verfasserin aut L. O. Petrov verfasserin aut E. V. Gameeva verfasserin aut In Тазовая хирургия и онкология “ABV-press” Publishing house”, LLC, 2021 8(2018), 4, Seite 34-46 (DE-627)176063123X 26869594 nnns volume:8 year:2018 number:4 pages:34-46 https://doi.org/10.17650/2220-3478-2018-8-4-34-46 kostenfrei https://doaj.org/article/ba1ad87a2f634b9f871c88d0ed32999d kostenfrei https://ok.abvpress.ru/jour/article/view/265 kostenfrei https://doaj.org/toc/2686-9594 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 8 2018 4 34-46 |
| allfieldsGer |
10.17650/2220-3478-2018-8-4-34-46 doi (DE-627)DOAJ030787157 (DE-599)DOAJba1ad87a2f634b9f871c88d0ed32999d DE-627 ger DE-627 rakwb rus RC254-282 M. V. Zabelin verfasserin aut New therapeutic agents for metastatic colorectal cancer: literature review 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This article provides an overview of drugs for metastatic colorectal cancer that are currently being evaluated in clinical trials. We discuss possible drug combinations and outlooks of their use in different lines of therapy. In addition to VEGF and EGFR inhibitors, we describe the molecules with fundamentally new mechanisms of action that can significantly expand the list of anticancer agents and increase the number of possible lines of therapy. colorectal cancer chemotherapy targeted drugs egfr inhibitors vegf inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens S. S. Gordeev verfasserin aut S. O. Kochkina verfasserin aut A. A. Kostin verfasserin aut A. A. Fedenko verfasserin aut L. O. Petrov verfasserin aut E. V. Gameeva verfasserin aut In Тазовая хирургия и онкология “ABV-press” Publishing house”, LLC, 2021 8(2018), 4, Seite 34-46 (DE-627)176063123X 26869594 nnns volume:8 year:2018 number:4 pages:34-46 https://doi.org/10.17650/2220-3478-2018-8-4-34-46 kostenfrei https://doaj.org/article/ba1ad87a2f634b9f871c88d0ed32999d kostenfrei https://ok.abvpress.ru/jour/article/view/265 kostenfrei https://doaj.org/toc/2686-9594 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 8 2018 4 34-46 |
| allfieldsSound |
10.17650/2220-3478-2018-8-4-34-46 doi (DE-627)DOAJ030787157 (DE-599)DOAJba1ad87a2f634b9f871c88d0ed32999d DE-627 ger DE-627 rakwb rus RC254-282 M. V. Zabelin verfasserin aut New therapeutic agents for metastatic colorectal cancer: literature review 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This article provides an overview of drugs for metastatic colorectal cancer that are currently being evaluated in clinical trials. We discuss possible drug combinations and outlooks of their use in different lines of therapy. In addition to VEGF and EGFR inhibitors, we describe the molecules with fundamentally new mechanisms of action that can significantly expand the list of anticancer agents and increase the number of possible lines of therapy. colorectal cancer chemotherapy targeted drugs egfr inhibitors vegf inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens S. S. Gordeev verfasserin aut S. O. Kochkina verfasserin aut A. A. Kostin verfasserin aut A. A. Fedenko verfasserin aut L. O. Petrov verfasserin aut E. V. Gameeva verfasserin aut In Тазовая хирургия и онкология “ABV-press” Publishing house”, LLC, 2021 8(2018), 4, Seite 34-46 (DE-627)176063123X 26869594 nnns volume:8 year:2018 number:4 pages:34-46 https://doi.org/10.17650/2220-3478-2018-8-4-34-46 kostenfrei https://doaj.org/article/ba1ad87a2f634b9f871c88d0ed32999d kostenfrei https://ok.abvpress.ru/jour/article/view/265 kostenfrei https://doaj.org/toc/2686-9594 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 8 2018 4 34-46 |
| language |
Russian |
| source |
In Тазовая хирургия и онкология 8(2018), 4, Seite 34-46 volume:8 year:2018 number:4 pages:34-46 |
| sourceStr |
In Тазовая хирургия и онкология 8(2018), 4, Seite 34-46 volume:8 year:2018 number:4 pages:34-46 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
colorectal cancer chemotherapy targeted drugs egfr inhibitors vegf inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| isfreeaccess_bool |
true |
| container_title |
Тазовая хирургия и онкология |
| authorswithroles_txt_mv |
M. V. Zabelin @@aut@@ S. S. Gordeev @@aut@@ S. O. Kochkina @@aut@@ A. A. Kostin @@aut@@ A. A. Fedenko @@aut@@ L. O. Petrov @@aut@@ E. V. Gameeva @@aut@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
176063123X |
| id |
DOAJ030787157 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ030787157</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501181613.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2018 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17650/2220-3478-2018-8-4-34-46</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ030787157</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJba1ad87a2f634b9f871c88d0ed32999d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">M. V. Zabelin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New therapeutic agents for metastatic colorectal cancer: literature review</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This article provides an overview of drugs for metastatic colorectal cancer that are currently being evaluated in clinical trials. We discuss possible drug combinations and outlooks of their use in different lines of therapy. In addition to VEGF and EGFR inhibitors, we describe the molecules with fundamentally new mechanisms of action that can significantly expand the list of anticancer agents and increase the number of possible lines of therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">colorectal cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">egfr inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">vegf inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. S. Gordeev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. O. Kochkina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. A. Kostin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. A. Fedenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">L. O. Petrov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. V. Gameeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Тазовая хирургия и онкология</subfield><subfield code="d">“ABV-press” Publishing house”, LLC, 2021</subfield><subfield code="g">8(2018), 4, Seite 34-46</subfield><subfield code="w">(DE-627)176063123X</subfield><subfield code="x">26869594</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:34-46</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17650/2220-3478-2018-8-4-34-46</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ba1ad87a2f634b9f871c88d0ed32999d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ok.abvpress.ru/jour/article/view/265</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2686-9594</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2018</subfield><subfield code="e">4</subfield><subfield code="h">34-46</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
M. V. Zabelin |
| spellingShingle |
M. V. Zabelin misc RC254-282 misc colorectal cancer misc chemotherapy misc targeted drugs misc egfr inhibitors misc vegf inhibitors misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens New therapeutic agents for metastatic colorectal cancer: literature review |
| authorStr |
M. V. Zabelin |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)176063123X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RC254-282 |
| illustrated |
Not Illustrated |
| issn |
26869594 |
| topic_title |
RC254-282 New therapeutic agents for metastatic colorectal cancer: literature review colorectal cancer chemotherapy targeted drugs egfr inhibitors vegf inhibitors |
| topic |
misc RC254-282 misc colorectal cancer misc chemotherapy misc targeted drugs misc egfr inhibitors misc vegf inhibitors misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_unstemmed |
misc RC254-282 misc colorectal cancer misc chemotherapy misc targeted drugs misc egfr inhibitors misc vegf inhibitors misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_browse |
misc RC254-282 misc colorectal cancer misc chemotherapy misc targeted drugs misc egfr inhibitors misc vegf inhibitors misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Тазовая хирургия и онкология |
| hierarchy_parent_id |
176063123X |
| hierarchy_top_title |
Тазовая хирургия и онкология |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)176063123X |
| title |
New therapeutic agents for metastatic colorectal cancer: literature review |
| ctrlnum |
(DE-627)DOAJ030787157 (DE-599)DOAJba1ad87a2f634b9f871c88d0ed32999d |
| title_full |
New therapeutic agents for metastatic colorectal cancer: literature review |
| author_sort |
M. V. Zabelin |
| journal |
Тазовая хирургия и онкология |
| journalStr |
Тазовая хирургия и онкология |
| callnumber-first-code |
R |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
txt |
| container_start_page |
34 |
| author_browse |
M. V. Zabelin S. S. Gordeev S. O. Kochkina A. A. Kostin A. A. Fedenko L. O. Petrov E. V. Gameeva |
| container_volume |
8 |
| class |
RC254-282 |
| format_se |
Elektronische Aufsätze |
| author-letter |
M. V. Zabelin |
| doi_str_mv |
10.17650/2220-3478-2018-8-4-34-46 |
| author2-role |
verfasserin |
| title_sort |
new therapeutic agents for metastatic colorectal cancer: literature review |
| callnumber |
RC254-282 |
| title_auth |
New therapeutic agents for metastatic colorectal cancer: literature review |
| abstract |
This article provides an overview of drugs for metastatic colorectal cancer that are currently being evaluated in clinical trials. We discuss possible drug combinations and outlooks of their use in different lines of therapy. In addition to VEGF and EGFR inhibitors, we describe the molecules with fundamentally new mechanisms of action that can significantly expand the list of anticancer agents and increase the number of possible lines of therapy. |
| abstractGer |
This article provides an overview of drugs for metastatic colorectal cancer that are currently being evaluated in clinical trials. We discuss possible drug combinations and outlooks of their use in different lines of therapy. In addition to VEGF and EGFR inhibitors, we describe the molecules with fundamentally new mechanisms of action that can significantly expand the list of anticancer agents and increase the number of possible lines of therapy. |
| abstract_unstemmed |
This article provides an overview of drugs for metastatic colorectal cancer that are currently being evaluated in clinical trials. We discuss possible drug combinations and outlooks of their use in different lines of therapy. In addition to VEGF and EGFR inhibitors, we describe the molecules with fundamentally new mechanisms of action that can significantly expand the list of anticancer agents and increase the number of possible lines of therapy. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA |
| container_issue |
4 |
| title_short |
New therapeutic agents for metastatic colorectal cancer: literature review |
| url |
https://doi.org/10.17650/2220-3478-2018-8-4-34-46 https://doaj.org/article/ba1ad87a2f634b9f871c88d0ed32999d https://ok.abvpress.ru/jour/article/view/265 https://doaj.org/toc/2686-9594 |
| remote_bool |
true |
| author2 |
S. S. Gordeev S. O. Kochkina A. A. Kostin A. A. Fedenko L. O. Petrov E. V. Gameeva |
| author2Str |
S. S. Gordeev S. O. Kochkina A. A. Kostin A. A. Fedenko L. O. Petrov E. V. Gameeva |
| ppnlink |
176063123X |
| callnumber-subject |
RC - Internal Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.17650/2220-3478-2018-8-4-34-46 |
| callnumber-a |
RC254-282 |
| up_date |
2024-07-03T16:58:31.347Z |
| _version_ |
1803577890016591872 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ030787157</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501181613.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2018 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17650/2220-3478-2018-8-4-34-46</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ030787157</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJba1ad87a2f634b9f871c88d0ed32999d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">M. V. Zabelin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New therapeutic agents for metastatic colorectal cancer: literature review</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This article provides an overview of drugs for metastatic colorectal cancer that are currently being evaluated in clinical trials. We discuss possible drug combinations and outlooks of their use in different lines of therapy. In addition to VEGF and EGFR inhibitors, we describe the molecules with fundamentally new mechanisms of action that can significantly expand the list of anticancer agents and increase the number of possible lines of therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">colorectal cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">egfr inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">vegf inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. S. Gordeev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. O. Kochkina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. A. Kostin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. A. Fedenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">L. O. Petrov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. V. Gameeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Тазовая хирургия и онкология</subfield><subfield code="d">“ABV-press” Publishing house”, LLC, 2021</subfield><subfield code="g">8(2018), 4, Seite 34-46</subfield><subfield code="w">(DE-627)176063123X</subfield><subfield code="x">26869594</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:34-46</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17650/2220-3478-2018-8-4-34-46</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ba1ad87a2f634b9f871c88d0ed32999d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ok.abvpress.ru/jour/article/view/265</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2686-9594</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2018</subfield><subfield code="e">4</subfield><subfield code="h">34-46</subfield></datafield></record></collection>
|
| score |
7.40149 |